David Whiteman

Transferrin receptor targeting chimeras for membrane protein degradation

Interim analyses of a first-in-human phase 1/2 mRNA trial for propionic acidaemia

Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: A perspective from the Hunter Outcome Survey (HOS)

Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome